These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8011008)

  • 1. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Barr J; Baillod RA
    Arzneimittelforschung; 1994 Apr; 44(4):522-6. PubMed ID: 8011008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
    Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN; Kontoghiorghes GJ
    Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Elimination of aluminum via continuous ambulatory peritoneal dialysis].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Jan; 114(1):9-13. PubMed ID: 2910699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
    Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
    Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous ambulatory peritoneal dialysis: three years' experience.
    Ramos JM; Gokal R; Siamopolous K; Ward MK; Wilkinson R; Kerr DN
    Q J Med; 1983; 52(206):165-86. PubMed ID: 6611839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
    Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.